8-KItem 5.02 · Officer/Director ChangeItem 9.01 · Financial Statements

Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…

Filed with the SEC on March 26, 2026 · Summarized by InvestorsBot

Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and an Interactive XBRL cover page (Exhibit 104). Filing signed Mar 26, 2026 by Richard Hoffman. 📄🔍 #SEC #8K #Incyte

No financial statements or amendments were included — this is an exhibit‑only 8‑K. Investors should review the Mar 25 press release for any material R&D, commercial or guidance updates. $INCY 📰⚠️ #biotech #investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from INCYTE CORP

Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.

8-K · March 26, 2026

FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…

8-K · March 6, 2026

Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…

8-K · February 10, 2026

Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY…

8-K · February 10, 2026

Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025.

8-K · December 12, 2025